Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Oncolytic vaccinia virus encoding constitutively active EPAC remodels the tumor microenvironment to enhance therapeutic efficacy with chemotherapy and surgery

Title: Oncolytic vaccinia virus encoding constitutively active EPAC remodels the tumor microenvironment to enhance therapeutic efficacy with chemotherapy and surgery
Authors: Siddharth Singh; Xiaohong He; Julia Thomas; Sydney Vallati; Julia Petryk; Bradley Austin; Stephen Boulton; Carolina Ilkow; Bailey Organ; Reza Rezaei; Rida Gill; Quanshen Guo; Jaahnavi Dave; Christiano Tanese De Souza; Amy Gingrich; Mathieu J F Crupi; Ragunath Singaravelu; John C Bell
Source: Journal for ImmunoTherapy of Cancer, Vol 14, Iss 1 (2026)
Publisher Information: BMJ Publishing Group
Publication Year: 2026
Collection: Directory of Open Access Journals: DOAJ Articles
Subject Terms: Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282
Description: Background Oncolytic viruses are tumor-specific immunotherapeutic agents that exploit inherent features of the tumor microenvironment to replicate, spread, and kill cancer cells. The exchange protein activated by cAMP (EPAC) is a cell signaling protein that regulates pathways important for cell growth, survival, and migration, which are commonly associated with cancer progression, but are also very important for regulation of viral infectivity. EPAC antagonism has been explored as a broad-spectrum antiviral strategy, while selective EPAC activation with cAMP analogs has been found to increase virus replication and enhance therapeutic outcome of oncolytic virotherapy. However, systemic EPAC agonism bears risk of cardiovascular complications and may potentiate cancer progression.Methods A constitutively active construct of EPAC was encoded into an oncolytic vaccinia virus (VV) and screened using plaque assays, spheroid infections, and Transwell migration assays for its ability to enhance virus replication and spread. In vivo luminescence imaging, titering and immunohistochemical staining was used to measure virus dissemination in primary injected tumors and to track their spread to distal untreated tumors. The impact of the VV-EPAC virus on the immune landscape of MC38 tumors was investigated by flow cytometry, ELISPOTs and cytokine ELISAs, while its overall therapeutic efficacy was explored in MC38, CT26LacZ, and B16F10 models. Combinational synergy was also tested with capecitabine and oxaliplatin chemotherapy, as well as with partial surgical resection.Results The EPAC-expressing virus exhibited an increase in migrative ability both in cell culture and in vivo, due in part to remodeling of the actin cytoskeleton leading to intercellular nanotube-like structures and enhanced syncytia formation. It reduced tumor burden and increased survival in multiple colorectal cancer models and reshaped the tumor microenvironment by inducing angiogenesis and recruiting CD8+T cells. The EPAC-expressing virus also synergized ...
Document Type: article in journal/newspaper
Language: English
Relation: https://jitc.bmj.com/content/14/1/e013832.full; https://doaj.org/toc/2051-1426; https://doaj.org/article/24da9f0d6665489999976752b69f04f0
DOI: 10.1136/jitc-2025-013832
Availability: https://doi.org/10.1136/jitc-2025-013832; https://doaj.org/article/24da9f0d6665489999976752b69f04f0
Accession Number: edsbas.7EE652EB
Database: BASE